Download presentation
Presentation is loading. Please wait.
Published byBuddy Dickerson Modified over 6 years ago
1
JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients by Marina Panova-Noeva, Marina Marchetti, Sabrina Buoro, Laura Russo, Annamaria Leuzzi, Guido Finazzi, Alessandro Rambaldi, Cosimo Ottomano, Hugo ten Cate, and Anna Falanga Blood Volume 118(9): September 1, 2011 ©2011 by American Society of Hematology
2
IPF parameters according to JAK2V617F mutation and therapy.
IPF parameters according to JAK2V617F mutation and therapy. Panels are showing: (A) platelet count, (B) IPF count, (C) percentage of IPF, and (D) percentage of H-IPF. Data are mean ± SD. CTR indicates controls; JAK2+, JAK2V617F-positive patients; JAK2−, JAK2V617F-negative patients. *P < .05 vs CTR. §P < .05 vs HU JAK2+. £P < .05 vs HU JAK2+, HU JAK2−. &P < .05 vs non-HU JAK2−, HU JAK2−, HU JAK2+. **P < .05 vs non-HU JAK2−. Marina Panova-Noeva et al. Blood 2011;118: ©2011 by American Society of Hematology
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.